Charles Schwab Investment Management Inc. Has $10.38 Million Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Charles Schwab Investment Management Inc. increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,284,036 shares of the company’s stock after buying an additional 14,558 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Bausch Health Companies were worth $10,375,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BHC. Goldentree Asset Management LP raised its stake in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after buying an additional 6,958,717 shares during the period. Bank of Montreal Can increased its holdings in Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. Maple Rock Capital Partners Inc. bought a new stake in Bausch Health Companies during the 3rd quarter worth approximately $16,850,000. SG Americas Securities LLC increased its holdings in Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Finally, Readystate Asset Management LP increased its holdings in Bausch Health Companies by 38.1% during the 3rd quarter. Readystate Asset Management LP now owns 470,761 shares of the company’s stock worth $3,841,000 after purchasing an additional 130,000 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on BHC. Royal Bank of Canada decreased their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.42.

Bausch Health Companies Stock Up 0.5 %

BHC stock opened at $7.17 on Friday. The business has a 50 day moving average of $7.14 and a 200-day moving average of $7.69. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $11.46. The firm has a market cap of $2.64 billion, a PE ratio of -59.70, a P/E/G ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. On average, research analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.